You just read:

Swedish Orphan Biovitrum AB - Long-term Safety and Efficacy Data of Extended Half-life Therapy Alprolix in Children With Haemophilia B Published in The Lancet Haematology

News provided by

Swedish Orphan Biovitrum AB

Feb 02, 2017, 07:46 ET